Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
MOORE JOHN R
General Counsel at Edgewise Therapeutics. Filing since 16 May 2022.
CIK 0001191702
Company
Date
Role
Action
Shares
Amount
Of holding
EWTX
Edgewise Therapeutics, Inc.
12 Aug 2026
General Counsel
Sold at will
5,016
$219.82K
22.1%
EWTX
Edgewise Therapeutics, Inc.
12 Aug 2025
General Counsel
Sold at will
2,098
$28.10K
17.0%
EWTX
Edgewise Therapeutics, Inc.
2 May 2025
General Counsel
Sold at will
1,930
$31.76K
22.8%
EWTX
Edgewise Therapeutics, Inc.
23 Sep 2024
General Counsel
Sold at will
20,922
$578.06K
86.5%
EWTX
Edgewise Therapeutics, Inc.
20 Sep 2024
General Counsel
Sold at will
50,000
$1.42M
93.9%
EWTX
Edgewise Therapeutics, Inc.
2 May 2024
General Counsel
Sold at will
1,956
$36.99K
37.6%
EWTX
Edgewise Therapeutics, Inc.
9 Feb 2024
General Counsel
Sold on a plan
8,029
$160.66K
100%
EWTX
Edgewise Therapeutics, Inc.
8 Feb 2024
General Counsel
Sold on a plan
3,813
$76.28K
100%
EWTX
Edgewise Therapeutics, Inc.
7 Feb 2024
General Counsel
Sold on a plan
17,993
$359.86K
100%
EWTX
Edgewise Therapeutics, Inc.
27 Dec 2023
General Counsel
Sold at will
8,497
$89.22K
100%
EWTX
Edgewise Therapeutics, Inc.
2 May 2023
General Counsel
Sold at will
1,897
$16.89K
22.4%
EWTX
Edgewise Therapeutics, Inc.
3 Oct 2022
General Counsel
Sold, plan not stated
4,730
$46.15K
61.2%
EWTX
Edgewise Therapeutics, Inc.
6 Sep 2022
General Counsel
Sold, plan not stated
4,730
$51.60K
61.2%
EWTX
Edgewise Therapeutics, Inc.
3 Aug 2022
General Counsel
Sold, plan not stated
9,232
$85.92K
75.5%
EWTX
Edgewise Therapeutics, Inc.
6 Jul 2022
General Counsel
Sold, plan not stated
1,046
$8.93K
25.9%
EWTX
Edgewise Therapeutics, Inc.
5 Jul 2022
General Counsel
Sold, plan not stated
8,186
$68.33K
73.2%
EWTX
Edgewise Therapeutics, Inc.
21 Jun 2022
General Counsel
Sold, plan not stated
31,078
$226.70K
91.2%
EWTX
Edgewise Therapeutics, Inc.
17 Jun 2022
General Counsel
Sold, plan not stated
22,127
$146.43K
88.1%
EWTX
Edgewise Therapeutics, Inc.
16 Jun 2022
General Counsel
Sold, plan not stated
14,722
$90.81K
83.1%
EWTX
Edgewise Therapeutics, Inc.
15 Jun 2022
General Counsel
Sold, plan not stated
18,660
$114.02K
86.1%
EWTX
Edgewise Therapeutics, Inc.
14 Jun 2022
General Counsel
Sold, plan not stated
3,628
$21.85K
54.7%
EWTX
Edgewise Therapeutics, Inc.
13 Jun 2022
General Counsel
Sold, plan not stated
4,093
$24.58K
57.7%
EWTX
Edgewise Therapeutics, Inc.
10 Jun 2022
General Counsel
Sold, plan not stated
7,125
$43.12K
70.4%
EWTX
Edgewise Therapeutics, Inc.
9 Jun 2022
General Counsel
Sold, plan not stated
7,615
$49.40K
71.7%
EWTX
Edgewise Therapeutics, Inc.
8 Jun 2022
General Counsel
Sold, plan not stated
12,566
$83.36K
80.7%
EWTX
Edgewise Therapeutics, Inc.
7 Jun 2022
General Counsel
Sold, plan not stated
18,123
$119.70K
85.8%
EWTX
Edgewise Therapeutics, Inc.
6 Jun 2022
General Counsel
Sold, plan not stated
13,934
$84.08K
82.3%
EWTX
Edgewise Therapeutics, Inc.
3 Jun 2022
General Counsel
Sold, plan not stated
15,230
$92.20K
83.5%
EWTX
Edgewise Therapeutics, Inc.
16 May 2022
General Counsel
Sold, plan not stated
10,800
$80.15K
78.3%
29 decisions on file.
